Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...
Low-density lipoprotein, known as LDL, is a complex structure with several components that allow cholesterol to circulate in the bloodstream, a watery environment. LDL is the primary mechanism used to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback